Sinopharm Group Co. Ltd. (01099) has released key unaudited financial figures of its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord, A shares: 000028; B shares: 200028), for the nine months ended 30 September 2025. According to the disclosure, Sinopharm Accord recorded total revenue of RMB 55.124 billion, reflecting a 2.38% decrease year-on-year, while net profit attributable to shareholders stood at RMB 0.957 billion, down 10.18% compared to the same period last year. Basic earnings per share declined 9.95% year-on-year, and weighted average return on net assets was 5.29%, marking a year-on-year decrease of 0.70 percentage point.
From July to September 2025, revenue amounted to RMB 18.328 billion, a year-on-year decrease of 1.89%. Corresponding net profit attributable to shareholders reached RMB 0.291 billion, down 9.58% from the same period in 2024. During this quarter, operating profit saw a slight increase of 2.88%, supported by business structure optimization, although provisions for credit impairment affected overall profitability.
In the distribution segment, January–September 2025 revenue was RMB 40.594 billion, down 0.59% year-on-year, while net profit decreased 7.32% to RMB 0.723 billion. Consistent market policy pressures and extended customer payment cycles led to higher credit impairment provisions, reducing distribution segment profits. The retail segment, operating under Sinopharm Holding Guoda Drugstore Co., Ltd., recorded revenue of RMB 15.226 billion, a 7.14% decrease year-on-year, but realized a net profit of RMB 13 million, representing a 133.91% jump. Sinopharm Accord attributed this improvement to optimized procurement, an emphasis on proprietary brands, and strategic store closures to reduce fixed costs.
The announcement emphasized Sinopharm Accord’s commitment to focusing on revenue growth, cost reduction, and efficiency enhancement in response to the evolving external environment, with a goal of maintaining stable, healthy development. It was also noted that these unaudited figures may differ from the final numbers in Sinopharm Accord’s official third-quarter report.